Graham G. Walmsley

Director Graham Walmsley purchases 200,000 shares across 3 trades (Mar 25-27) for $8.8M at blended avg $43.94

Graham G. Walmsley (Director) executed 3 separate purchases totaling 200,000 shares for $8,787,921.11 over three consecutive trading days at prices ranging from $43.01 to $44.75, increasing his stake by 20% to 1.20M shares. His prior 4 purchases at AKRO all achieved positive 90-day returns (+37.4% to +61.2%), establishing a demonstrated pattern of well-timed entry points at this ticker. However, this buying occurs while the company is unprofitable with a net loss of $-72,705,000.00 over its most recent full fiscal year, and the stock is currently 24.3% below its 52-week high despite a +54.3% 90-day rally. The scale of this acquisition ($8.8M) and timing pattern warrant examination of what fundamental or technical signals motivated this substantial director-level commitment during a period of ongoing losses.

Director Graham G. Walmsley purchased 200,000 shares of Akero (AKRO) at $48.00 on 2025-01-30 for $9,600,000; 4 of 5 prior same-ticker buys showed +55.5% to +61.2% 90-day returns.

Walmsley purchased 200,000 shares (+25.0% vs pre-transaction holdings) at $48.00, bringing his total stake to 1,000,000 shares. This represents a substantial open-market commitment of $9.6M. His prior trades at AKRO show a strong pattern: 4 of 5 previous buys were well-timed at the 90-day mark, with returns ranging from +55.5% to +61.2%. However, the company remains unprofitable with net income of $-72.7M over its most recent full fiscal year. The stock has appreciated +107.2% over the past 30 days and +57.4% over 90 days, currently trading at $54.21 versus the transaction price of $48.00. This purchase occurs after substantial near-term momentum and against a backdrop of fundamental losses, warranting deeper scrutiny into the investment thesis.

Director Walmsley sold and bought 700,761 shares at $6.75 simultaneously on 2024-12-17; stock down 33.0% in 30 days.

Graham G. Walmsley, a Director at Olema Pharmaceuticals, executed 2 offsetting transactions on 2024-12-17: a sale of 700,761 shares at $6.75 for $4,730,136.75 and an immediate purchase of 700,761 shares at $6.75 for $4,730,136.75. This simultaneous buy-sell at the same price and volume suggests a technical or tax-motivated transaction rather than a market conviction signal. The company reported net income of $-34,555,000.00 over its most recent full fiscal year and trades at $6.14 today, down 33.0% over the past 30 days and 52.1% over 90 days. While Walmsley's prior OLMA trades show mixed timing (3 of 5 well-timed at the 90-day mark), his cross-ticker track record shows 2 prior sells with a 100.00% well-timed rate, though the stock has declined sharply since this filing date. The offsetting nature of this transaction and the unprofitable fundamentals warrant examination of the underlying mechanics and context.